La cadena de opciones muestra datos clave de las opciones de acciones de CARISMA Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CARISMA Therapeutics..

CARISMA Therapeutics (NASDAQ:CARM) Bolsa, Cadena de Opciones

CARISMA THERAPEUTICS INC

CARISMA Therapeutics

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics Inc

CARMAT ORD by Carmat

CARMELL CORPORATION WT EXP

CarMax Inc

Carmila SA

Lake Street analyst Ben Klieve maintains S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) with a Buy and lowers the price target from $35 to $25.

News

Price Target

Analyst Ratings

SANW

Lake Street Maintains Buy on S&W Seed, Lowers Price Target to $25

Michael Burry, famed for his highly profitable bet against the U.S. housing market in 2008, has recently shifted to a bearish stance on Chinese <a href="https://www.benzinga.com/markets/equities/25/05/45461072/the-big-short-fame-michael-burry-doubled-estee-lauder-stake-despite-slump-bet-against-nvidia-and-dumps-china-stocks-amid-trade-war-jitters-in-q1">technology stocks.</a>
Burry's pivot is notable because he was previously bullish on China tech companies and held significant long positions in companies like Alibaba Group Holdings, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and JD.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) as recently as late 2024. 
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45471661/coinbase-under-sec-investigation-for-overstatement-of-user-numbers?utm_source=articleShare">Coinbase Under SEC Investigation For Overstatement Of User Numbers&nbsp;</a>
However, the latest SEC filings show a marked reversal: Burry's hedge fund, Scion Asset Management,&nbsp; acquired put options against several major Chinese tech companies.&nbsp;
The Details: In the first quarter of 2025, Burry completely liquidated his previous positions in Alibaba, JD.Com, Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and PDD Holdings Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and purchased put options on each of the Chinese tech names.&nbsp;
Burry's bearish pivot on China came in the quarter before the announcement of new tariffs on Chinese goods by President Donald Trump, which heightened trade tensions and roiled global markets. The timing suggests the experienced investor anticipated increased volatility or downside risk in Chinese equities amid geopolitical and economic uncertainty.&nbsp;
Scion also purchased a sizable amount of put options on NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the first quarter, which now makes up nearly half of its portfolio.&nbsp;
The hedge fund's only long position in the most recent quarter's filing was Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>).&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a></li>
</ul>
Photo: Pla2na via Shutterstock

Options

Global

Markets

Movers

Tech

BABA

BIDU

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

'Big Short' Investor Michael Burry Turns Bearish On China: What's On His Short List Now

JP Morgan analyst Ann Duignan maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Overweight and raises the price target from $110 to $117.

AGCO

JP Morgan Maintains Overweight on AGCO, Raises Price Target to $117

General

CaliberCos  Regains Nasdaq Listing Compliance for Minimum Bid Price

TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) has outperformed the market over the past 20 years by 6.21% on an annualized basis producing an average annual return of 14.56%. Currently, TD Synnex has a market capitalization of $10.41 billion. 
Buying $100 In SNX: If an investor had bought $100 of SNX stock 20 years ago, it would be worth $1,519.28 today based on a price of $125.05 for SNX at the time of writing.
<h3>TD Synnex's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747430124_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

JP Morgan analyst Stephen Tusa maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Overweight and raises the price target from $100 to $127.

JP Morgan Maintains Overweight on Vertiv Holdings, Raises Price Target to $127

JP Morgan analyst Stephen Tusa maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Overweight and raises the price target from $190 to $211.

JP Morgan Maintains Overweight on Dover, Raises Price Target to $211

JP Morgan analyst Stephen Tusa maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $78 to $93.

JP Morgan Maintains Overweight on DuPont de Nemours, Raises Price Target to $93

Offerings

MetLife Files For Mixed Shelf; Size Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) stock rose 6.6% to $2.25 during Friday's after-market session. The company's market cap stands at $23.5 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares moved upwards by 5.15% to $0.61. The company's market cap stands at $15.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Intelligent Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) stock increased by 4.93% to $0.59. The company's market cap stands at $7.8 million. </li>
<li>Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) shares increased by 4.93% to $1.7. The market value of their outstanding shares is at $74.6 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) shares increased by 4.61% to $1.36. The market value of their outstanding shares is at $76.4 million. </li>
<li>Kartoon Studios (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOON#AMEX">TOON</a>) shares rose 4.54% to $0.88. The company's market cap stands at $41.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Stran &amp; Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) stock decreased by 6.2% to $1.21 during Friday's after-market session. The market value of their outstanding shares is at $22.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) shares declined by 5.4% to $0.17. The market value of their outstanding shares is at $2.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Token Cat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) shares declined by 3.98% to $0.71. The market value of their outstanding shares is at $2.2 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares fell 3.89% to $0.1. The company's market cap stands at $1.4 million. </li>
<li>CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) shares declined by 3.88% to $5.7. The market value of their outstanding shares is at $327.2 million. </li>
<li>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) shares decreased by 3.87% to $5.1. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLMZ

CREX

CURI

INTJ

LILA

MCHX

NIPG

NXPL

SWAG

TOON

12 Communication Services Stocks Moving In Friday's After-Market Session

JP Morgan analyst Stephen Tusa maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Neutral and raises the price target from $113 to $133.

JP Morgan Maintains Neutral on Emerson Electric, Raises Price Target to $133

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 45.0% to $1.74 during Friday's after-market session. The company's market cap stands at $23.9 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares moved upwards by 16.2% to $0.35. The company's market cap stands at $50.8 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock increased by 15.88% to $1.53. The market value of their outstanding shares is at $3.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 9.24% to $10.75. The market value of their outstanding shares is at $2.0 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 8.86% to $0.01. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 8.13% to $1.33. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.4% to $0.57 during Friday's after-market session. The market value of their outstanding shares is at $17.7 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 8.83% to $6.55. The company's market cap stands at $352.3 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock decreased by 5.99% to $2.2. The company's market cap stands at $3.6 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares fell 5.85% to $1.45. The company's market cap stands at $47.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 5.16% to $4.05. The company's market cap stands at $2.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares fell 5.0% to $0.8. The company's market cap stands at $105.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

DRRX

ENSC

ENVB

HCTI

PEPG

PRTA

RAPT

SSII

SXTC

TIVC

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) shares rose 6.7% to $0.95 during Friday's after-market session. The company's market cap stands at $147.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares rose 5.59% to $0.94. The company's market cap stands at $3.9 million. </li>
<li>C3is (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock increased by 4.93% to $3.83. The market value of their outstanding shares is at $2.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) stock moved upwards by 4.06% to $1.79. The market value of their outstanding shares is at $14.2 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) shares moved upwards by 3.88% to $1.58. The market value of their outstanding shares is at $182.8 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares increased by 3.84% to $0.9. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) shares fell 10.9% to $2.3 during Friday's after-market session. The company's market cap stands at $264.0 million. </li>
<li>First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) shares decreased by 7.67% to $16.75. The market value of their outstanding shares is at $2.9 billion. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock declined by 6.72% to $0.55. The company's market cap stands at $3.3 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares declined by 5.84% to $4.68. The company's market cap stands at $60.7 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock decreased by 5.4% to $6.02. The market value of their outstanding shares is at $3.6 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares fell 4.8% to $0.15. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXG

CISS

LICN

NRGV

SGLY

VSTE

ZONE

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares increased by 77.5% to $1.81 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) shares moved upwards by 6.61% to $0.58. The company's market cap stands at $36.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) stock increased by 6.38% to $4.0. The company's market cap stands at $40.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares moved upwards by 6.06% to $0.5. The market value of their outstanding shares is at $14.1 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock rose 5.54% to $0.54. The market value of their outstanding shares is at $20.2 million. The company's, Q2 earnings came out 2 days ago. </li>
<li>WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) stock moved upwards by 5.52% to $1.14. The market value of their outstanding shares is at $119.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Semilux International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) stock fell 11.4% to $1.64 during Friday's after-market session. The company's market cap stands at $61.3 million. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares decreased by 10.47% to $0.16. The market value of their outstanding shares is at $9.3 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) stock declined by 6.86% to $0.25. The company's market cap stands at $3.3 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares fell 6.34% to $3.55. The company's market cap stands at $8.4 million. </li>
<li>SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) shares fell 5.93% to $0.81. The market value of their outstanding shares is at $152.5 million. </li>
<li>Datasea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTSS#NASDAQ">DTSS</a>) stock decreased by 5.21% to $2.55. The market value of their outstanding shares is at $19.0 million. The company's, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

BTOG

CMBM

DTSS

LDTC

MAPS

MOVE

PXLW

SELX

SMRT

TACT

TAOP

12 Information Technology Stocks Moving In Friday's After-Market Session

Birks Group Receives NYSE American Approval of Submitted Compliance Plan

JP Morgan analyst Stephen Tusa maintains Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) with a Neutral and raises the price target from $182 to $217.

JP Morgan Maintains Neutral on Honeywell Intl, Raises Price Target to $217

JP Morgan analyst Stephen Tusa maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Neutral and raises the price target from $334 to $400.

JP Morgan Maintains Neutral on Trane Technologies, Raises Price Target to $400

LOBO

LOBO Receives Nasdaq Minimum Bid Price Notification

11 analysts have shared their evaluations of NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for NOV, presenting an average target of $16.27, a high estimate of $23.00, and a low estimate of $11.00. A 8.23% drop is evident in the current average compared to the previous average price target of $17.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1747429286_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of NOV's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NOV. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NOV compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NOV's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of NOV's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NOV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NOV analyst ratings.</a>
<h2>Unveiling the Story Behind NOV</h2>
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
<h3>Understanding the Numbers: NOV's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: NOV's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -2.41%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: NOV's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.47%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): NOV's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.14%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NOV's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.65%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NOV's debt-to-equity ratio is below the industry average. With a ratio of 0.37, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NOV Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Across the recent three months, 9 analysts have shared their insights on Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Chart Industries, revealing an average target of $197.78, a high estimate of $250.00, and a low estimate of $160.00. A 3.89% drop is evident in the current average compared to the previous average price target of $205.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1747429271_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Chart Industries. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$214.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chart Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chart Industries compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Chart Industries's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Chart Industries's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GTLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chart Industries analyst ratings.</a>
<h2>Unveiling the Story Behind Chart Industries</h2>
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company.
<h3>Financial Milestones: Chart Industries's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Chart Industries displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.34%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Chart Industries's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chart Industries's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.47%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Chart Industries's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.46%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.24, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLS

9 Analysts Have This To Say About Chart Industries

Penny Stocks

Press Releases

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Earnings

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Comments

CARISMA Therapeutics

CARISMA Therapeutics (CARM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL